Published in Breast Cancer Res on May 31, 2006
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol (2010) 3.79
An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat (2007) 2.65
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med (2009) 2.33
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol (2011) 2.26
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat (2011) 2.08
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract (2007) 1.97
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol (2010) 1.47
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res (2011) 1.30
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol (2010) 1.17
Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue. PLoS One (2012) 1.17
Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst (2014) 1.16
Barriers to the use of personalized medicine in breast cancer. J Oncol Pract (2012) 1.15
Cryotherapy for breast cancer: a feasibility study without excision. J Vasc Interv Radiol (2009) 1.13
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev (2014) 1.11
Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol (2008) 1.07
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg (2011) 1.05
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer (2012) 1.04
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer (2011) 1.04
Automated quantification of aligned collagen for human breast carcinoma prognosis. J Pathol Inform (2014) 1.03
Factors influencing the statistical power of complex data analysis protocols for molecular signature development from microarray data. PLoS One (2009) 1.02
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser (2010) 1.01
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. J Magn Reson Imaging (2015) 0.96
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract (2013) 0.96
Future directions for the early detection of recurrent breast cancer. J Cancer (2014) 0.95
Gene expression profiling of breast cancer. Adv Surg (2008) 0.94
The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment. Oncologist (2015) 0.94
Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach. J Cancer Res Clin Oncol (2010) 0.93
Who gets genomic testing for breast cancer recurrence risk? Public Health Genomics (2013) 0.91
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat (2013) 0.91
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One (2013) 0.88
Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer. PLoS One (2009) 0.86
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res (2013) 0.86
Understanding how breast cancer patients use risk information from genomic tests. J Behav Med (2012) 0.86
Pan-Cancer Analyses Reveal Long Intergenic Non-Coding RNAs Relevant to Tumor Diagnosis, Subtyping and Prognosis. EBioMedicine (2016) 0.85
Comprehensive molecular screening: from the RT-PCR to the RNA-seq. Transl Lung Cancer Res (2013) 0.83
Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol (2009) 0.83
Signatures of breast cancer metastasis at a glance. J Cell Sci (2016) 0.82
A radiation-derived gene expression signature predicts clinical outcome for breast cancer patients. Radiat Res (2009) 0.82
Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer. BMC Cancer (2009) 0.82
Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget (2015) 0.82
Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med (2009) 0.81
Review of the clinical studies using the 21-gene assay. Oncologist (2010) 0.81
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer? Genet Med (2015) 0.81
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients. EPMA J (2010) 0.81
Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care (2016) 0.81
Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog (2013) 0.80
Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma? Breast J (2015) 0.80
Unraveling human complexity and disease with systems biology and personalized medicine. Per Med (2010) 0.80
Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer. Ann Surg (2016) 0.80
The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy. Ecancermedicalscience (2013) 0.79
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Adv Med (2014) 0.79
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. J Oncol Pract (2016) 0.79
Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France. PLoS One (2015) 0.79
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncol (2012) 0.79
Histopathological and genomic grading provide complementary prognostic information in breast cancer: a study on publicly available datasets. Patholog Res Int (2011) 0.79
E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer. Mol Cancer Res (2015) 0.79
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Res (2016) 0.79
Benefits, issues, and recommendations for personalized medicine in oncology in Canada. Curr Oncol (2013) 0.78
Gene expression profiling: changing face of breast cancer classification and management. Gene Expr (2011) 0.78
Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score. Appl Immunohistochem Mol Morphol (2016) 0.78
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer. Am J Clin Oncol (2014) 0.78
Is the thymidine labeling index a good prognostic marker in breast cancer? World J Surg Oncol (2007) 0.78
A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. Adv Ther (2015) 0.78
Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. Curr Oncol (2009) 0.78
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. J Natl Compr Canc Netw (2015) 0.78
Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep (2013) 0.78
The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study. Br J Cancer (2016) 0.78
Postoperative fever: the potential relationship with prognosis in node negative breast cancer patients. PLoS One (2010) 0.77
Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. BMC Cancer (2015) 0.77
Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer. PLoS One (2014) 0.77
Adopting nested case-control quota sampling designs for the evaluation of risk markers. Lifetime Data Anal (2013) 0.77
Implementation of the 21-gene recurrence score test in the United States in 2011. Genet Med (2016) 0.77
Gene expression profiling in breast cancer. Am J Transl Res (2013) 0.77
A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. Rev Urol (2014) 0.77
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer (2017) 0.77
Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer. Clin Exp Metastasis (2009) 0.76
Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas? Patholog Res Int (2010) 0.76
Application of cancer-associated glycoforms and glycan-binding probes to an in vitro diagnostic multivariate index assay for precise diagnoses of cancer. Proteomics (2016) 0.76
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use? Breast Cancer Res Treat (2012) 0.76
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. Front Oncol (2016) 0.76
Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis. Microarrays (Basel) (2013) 0.75
Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound. J Am Coll Surg (2016) 0.75
Atomic force microscopic detection enabling multiplexed low-cycle-number quantitative polymerase chain reaction for biomarker assays. Anal Chem (2014) 0.75
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl (2013) 0.75
Tumor gene expression profiling in women with breast cancer. Test category: prognostic. PLoS Curr (2010) 0.75
The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures. BMC Cancer (2016) 0.75
Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. Clin Breast Cancer (2015) 0.75
Estimating the OncotypeDX score: validation of an inexpensive estimation tool. Breast Cancer Res Treat (2016) 0.75
The analytical validation of the Oncotype DX Recurrence Score assay. Ecancermedicalscience (2016) 0.75
Genome-based risk prediction for early stage breast cancer. Oncologist (2014) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health (1992) 20.06
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 12.78
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol (2004) 5.29
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst (2005) 3.18
Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. J Clin Oncol (2004) 3.03
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol (1995) 2.63
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol (2001) 2.36
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Trends in breast cancer by race and ethnicity. CA Cancer J Clin (2004) 2.19
Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet (2000) 2.15
Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol (2005) 1.94
Estimation of absolute risk from nested case-control data. Biometrics (1997) 1.77
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res (2005) 1.64
Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol (2002) 1.63
The frequency of kidney and urinary tract diseases in a defined population. Kidney Int (1982) 1.49
Individualized care for patients with cancer - a work in progress. N Engl J Med (2004) 1.42
Some evidence refuting the HMO "favorable selection" hypothesis: the case of Kaiser Permanente. Adv Health Econ Health Serv Res (1991) 1.33
Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer (1986) 1.25
When is a genomic classifier ready for prime time? Nat Clin Pract Oncol (2004) 1.06
NCCN: Breast cancer. Cancer Control (2001) 0.99
Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Dis (2004) 0.98
Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance. Pathol Res Pract (1990) 0.98
Genomic approaches in the management and treatment of breast cancer. Br J Cancer (2005) 0.97
Observer variation in histological grading of breast cancer. Eur J Surg Oncol (1989) 0.95
Gene expression profiling of primary breast cancer. Curr Oncol Rep (2005) 0.87
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54
Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 6.09
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA (2009) 5.75
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ (2005) 5.34
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol (2004) 5.29
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol (2005) 4.66
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol (2010) 4.43
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol (2010) 3.79
An increase in the incidence of gestational diabetes mellitus: Northern California, 1991-2000. Obstet Gynecol (2004) 3.77
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol (2008) 3.66
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat (2010) 3.35
Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr (2002) 3.33
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol (2013) 3.18
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem (2007) 3.05
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol (2007) 2.93
COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest (2005) 2.88
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry (2005) 2.60
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr (2003) 2.55
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol (2008) 2.55
Racial/ethnic variation in asthma status and management practices among children in managed medicaid. Pediatrics (2002) 2.54
What a professor learned about Cyclospora cayetanensis by attending Digestive Diseases Week conference in Chicago. Am J Gastroenterol (2012) 2.52
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol (2005) 2.47
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol (2009) 2.34
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation (2003) 2.32
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol (2010) 2.28
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat (2007) 2.27
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol (2011) 2.26
Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res (2007) 2.19
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol (2013) 2.12
Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol (2004) 2.11
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat (2011) 2.08
Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med (2007) 2.07
Evaluation of potential confounders in planning a study of occupational magnetic field exposure and female breast cancer. Epidemiology (2002) 2.06
Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med (2010) 2.04
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res (2004) 2.03
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.02
Prepregnancy SHBG concentrations and risk for subsequently developing gestational diabetes mellitus. Diabetes Care (2014) 1.98
Maternal and grandmaternal smoking patterns are associated with early childhood asthma. Chest (2005) 1.98
Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study. Cancer Epidemiol Biomarkers Prev (2009) 1.95
Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.94
Lactation intensity and postpartum maternal glucose tolerance and insulin resistance in women with recent GDM: the SWIFT cohort. Diabetes Care (2011) 1.93
Childbearing may increase visceral adipose tissue independent of overall increase in body fat. Obesity (Silver Spring) (2008) 1.91
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst (2010) 1.91
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol (2013) 1.81
Cigarette smoking and cancer risk: modeling total exposure and intensity. Am J Epidemiol (2007) 1.80
Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control (2009) 1.79
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res (2005) 1.78